drugset / Trial / NCT07285473
Low-Dose Naltrexone For ME/CFS: Dose-Finding
Phase 2
Not yet recruiting
75 enrolled
University of Alabama at Birmingham
National Institute of Neurological Disorders and Stroke (NINDS) · collab
NaSingle-groupOpen-labelTreatment
Summary
This exploratory clinical trial tests low-dose naltrexone (LDN) for the treatment of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome (ME/CFS). A remote trial approach is used, with eligibility open to the state of Alabama.
Timeline
- Start
- 2026-11-01
- Primary completion
- 2028-04-01
- Completion
- 2028-04-01
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Naltrexone | Small molecule | 1.5 mg | Oral |
| Subject | Naltrexone | Small molecule | 3 mg | Oral |
| Subject | Naltrexone | Small molecule | 4.5 mg | Oral |
| Subject | Naltrexone | Small molecule | 6 mg | Oral |